The burden of neovascular age-related macular degeneration: a patient’s perspective

Código QR

The burden of neovascular age-related macular degeneration: a patient’s perspective

Kimberly L Spooner,1,2 Cleopatra T Mhlanga,1 Thomas H Hong,1 Geoffrey K Broadhead,1 Andrew A Chang1,2 1Sydney Institute of Vision Science, Sydney Retina, Sydney, NSW, Australia; 2Save Sight Institute, University of Sydney, Sydney, NSW, Australia Purpose: To quantify the burden and quality of life of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Burden treatment anti-VEGF age-related macular degeneration Australia Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c574bc2573a74331bfdb03eefea0a587
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration – Current Perspectives
por: Phan LT, et al.
Publicado: (2021)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration
por: Sobolewska B, et al.
Publicado: (2021)

Recent developments in age-related macular degeneration: a review
por: Al-Zamil WM, et al.
Publicado: (2017)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)

Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia
por: Spooner KL, et al.
Publicado: (2019)

Specific Autoantibodies in Neovascular Age-Related Macular Degeneration: Evaluation of Morphological and Functional Progression over Five Years
por: Michelle Prasuhn, et al.
Publicado: (2021)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon SD, et al.
Publicado: (2021)

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
por: Iida T, et al.
Publicado: (2016)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Medication Trends for Age-Related Macular Degeneration
por: Yeon-Kyoung Cho, et al.
Publicado: (2021)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)

The Influence of Blue-Filtering Intraocular Lenses Implant on Exudative Age-Related Macular Degeneration: A Case–Control Study
por: Hamel T, et al.
Publicado: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study
por: Karagiannis DA, et al.
Publicado: (2020)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Circulating monocytes and B-lymphocytes in neovascular age-related macular degeneration
por: Hector SM, et al.
Publicado: (2017)

The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano M, et al.
Publicado: (2016)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Associations of ARMS2 and CFH Gene Polymorphisms with Neovascular Age-Related Macular Degeneration
por: Supanji S, et al.
Publicado: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Implantation of the First IMT Macular Lens in Age-Related Macular Degeneration (Literature Review)
por: M. M. Bikbov, et al.
Publicado: (2019)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular Degeneration Patients
por: Sabrina L. Mitchell, et al.
Publicado: (2021)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy B, et al.
Publicado: (2020)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi S, et al.
Publicado: (2021)

Agreement of swept-source and spectral-domain optical coherence-tomography retinal thickness measurements in neovascular age-related macular degeneration
por: Hanumunthadu D, et al.
Publicado: (2017)